AGP Picks
View all

Nutrition BioTech guide maps Urolithin A regulatory records by market

Nov. 16, 2026
Nutrition BioTech guide maps Urolithin A regulatory records by market
By AI, Created 18:06 UTC, Nov 16, 2026, AGP -

Nutrition BioTech has released a Urolithin A buyer guide that separates U.S. food, U.S. supplement, Great Britain and EU regulatory records so brands can match the right document to the right product. The guide also gives buyers a checklist to verify whether a supplier’s powder, process and specifications actually fit the record being cited.

Why it matters: - Urolithin A buyers often face a fast-moving regulatory question: whether a supplier’s cited record actually covers the intended market, product type and material. - The guide is designed to help supplement brands and contract manufacturers avoid relying on a record that does not match the finished product. - The guide frames a missing document as a gap to resolve, not proof that a supplier is non-compliant.

What happened: - Nutrition BioTech (NaturalBestBio) published a November 1, 2026 guide on Urolithin A regulatory records for buyers. - The guide breaks out U.S. food, U.S. dietary supplement, Great Britain and EU pathways instead of treating all Urolithin A records as interchangeable. - The guide also provides buyer questions to send to suppliers before purchase.

The details: - For U.S. conventional foods, the guide points to FDA’s December 20, 2018 response letter to GRAS Notice No. 791. - For U.S. dietary supplements, the guide points to the new dietary ingredient notification process under 21 CFR 190.6. - Under that process, a manufacturer or distributor notifies FDA at least 75 days before interstate marketing unless a statutory exception applies. - For Great Britain, the guide says the Food Standards Agency register listed application RP1777 as in progress at the risk assessment stage when checked on November 1, 2026. - For the European Union, the guide says the European Commission summary listed the EU application as ongoing when checked on November 1, 2026. - The guide says GRN 791 covers the notifier’s GRAS conclusion for the food uses listed in the notice. - The guide says the notice describes chemically synthesized material at 97% purity or higher. - The guide says the FDA letter is not an affirmation of GRAS status. - The guide says the FDA letter does not mention dietary supplements. - The buyer checklist asks suppliers to identify the governing document, the submitter, the production route, the exact specification match and the intended use level. - For U.S. supplements, the checklist asks whether an NDI notification exists for the material or what basis supports a conclusion that one is not needed.

Between the lines: - The guide is pushing buyers to separate regulatory status from marketing language. - A supplier name-dropping “GRN 791” is not enough on its own, because the same record may not cover the buyer’s market, use case or material source. - The emphasis on “whose record” matters because a third-party document may not apply to a different manufacturer’s powder or production route. - The guide also signals that buyers should verify both regulatory scope and material identity before treating a document as usable support.

What's next: - Buyers are expected to use the guide’s checklist in supplier outreach and procurement review. - The guide directs buyers to ask for lot-specific support before purchase, including the document that applies to the exact material offered. - Nutrition BioTech says every lot ships with a lot-specific Certificate of Analysis, and qualified buyers can review lot COAs and supporting records before purchase.

The bottom line: - For Urolithin A, the key question is not just whether a record exists, but whether it matches the market, use and material on offer. - Nutrition BioTech’s guide turns that into a practical supplier-verification checklist for bulk buyers.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.